In last trading session, Emergent Biosolutions Inc (NYSE:EBS) saw 1.26 million shares changing hands with its beta currently measuring 1.21. Company’s recent per share price level of $2.51 trading at $0.05 or 2.03% at ring of the bell on the day assigns it a market valuation of $131.02M. That closing price of EBS’s stock is at a discount of -444.62% from its 52-week high price of $13.67 and is indicating a premium of 43.43% from its 52-week low price of $1.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.3 million shares which gives us an average trading volume of 3.13 million if we extend that period to 3-months.
Emergent Biosolutions Inc (NYSE:EBS) trade information
Upright in the green during last session for gaining 2.03%, in the last five days EBS remained trading in the green while hitting it’s week-highest on Wednesday, 03/20/24 when the stock touched $2.51 price level, adding 2.71% to its value on the day. Emergent Biosolutions Inc’s shares saw a change of 4.58% in year-to-date performance and have moved 12.05% in past 5-day. Emergent Biosolutions Inc (NYSE:EBS) showed a performance of 65.13% in past 30-days. Number of shares sold short was 6.2 million shares which calculate 1.11 days to cover the short interests.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Statistics highlight that Emergent Biosolutions Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -33.24% of value to its shares in past 6 months, showing an annual growth rate of 140.29% while that of industry is 12.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 73.80% in the current quarter and calculating 40.60% increase in the next quarter. This year revenue growth is estimated to fall -2.30% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $224.5 million for the same. And 1 analysts are in estimates of company making revenue of $244.5 million in the next quarter that will end on Jun 2024.
EBS Dividends
Emergent Biosolutions Inc is more likely to be releasing its next quarterly report between May 07 and May 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
Insiders are in possession of 2.89% of company’s total shares while institution are holding 79.85 percent of that, with stock having share float percentage of 82.22%. Investors also watch the number of corporate investors in a company very closely, which is 79.85% institutions for Emergent Biosolutions Inc that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at EBS for having 9.23 million shares of worth $67.85 million. And as of Jun 29, 2023, it was holding 17.82% of the company’s outstanding shares.
The second largest institutional holder is State Street Corporation, which was holding about 6.79 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 13.11% of outstanding shares, having a total worth of $49.94 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 4.9 million shares of worth $22.99 million or 9.46% of the total outstanding shares. The later fund manager was in possession of 1.44 million shares on Jun 29, 2023, making its stake of worth around $10.61 million in the company or a holder of 2.79% of company’s stock.
